FDA Approves Rusfertide (Mimrylo) for Polycythemia Vera — A New Tool to Control Hematocrit Without Phlebotomy

Polycythemia vera is a JAK2-driven myeloproliferative neoplasm that causes uncontrolled production of red blood cells, pushing hematocrit to dangerous levels. The elevated hematocrit is the problem — it increases blood viscosity, thrombosis risk, and ultimately the risk of stroke, heart attack, and clot in atypical sites like mesenteric and portal veins. The standard of care for controlling hematocrit has been phlebotomy — literally removing blood — which reduces viscosity but does not address the underlying marrow overproduction. The irony is that phlebotomy depletes iron, which partially suppresses erythropoiesis, creating iron deficiency as a therapeutic mechanism. Rusfertide exploits that same biology more precisely. It is a synthetic hepcidin mimetic — a molecule that directly mimics hepcidin, the body's master regulator of iron availability — and by restricting iron supply to the bone marrow, it limits red cell production without the inconvenience and discomfort of repeated therapeutic phlebotomies.[1]

The VERIFY trial enrolled 293 adults with PV who required phlebotomy for hematocrit control, randomizing them to rusfertide plus standard-of-care cytoreductive therapy versus placebo plus standard-of-care. The primary endpoint — clinical response at weeks 20 through 32, defined as maintaining hematocrit below 45% without qualifying phlebotomy — was achieved by 76.9% of rusfertide patients versus 32.9% of placebo patients. That is a 44-percentage-point absolute difference, and it was highly statistically significant. Secondary endpoints reinforced the primary: patients on rusfertide required a mean of 0.5 phlebotomies during the treatment period compared with 1.8 in the control group, and 62.6% maintained sustained hematocrit below 45% compared with 14.4%.[2]

The FDA approved rusfertide under the brand name Mimrylo on August 28, 2026, for adults with PV who require phlebotomy — making it the first hepcidin mimetic approved in the United States for any indication.

Mechanism and Clinical Context

Hepcidin is a peptide hormone produced by the liver that controls systemic iron homeostasis. It binds and degrades ferroportin — the transporter that moves iron out of cells into the bloodstream — thereby sequestering iron in enterocytes, macrophages, and hepatocytes and reducing iron available for erythropoiesis. In PV, the bone marrow is biologically capable of outrunning iron supply if iron is abundant. By elevating effective hepcidin signaling, rusfertide creates a pharmacologically managed functional iron deficiency that slows red cell production. Unlike actual phlebotomy-induced iron deficiency, the approach is titratable and does not produce the symptoms of systemic iron deficiency (fatigue, restless legs, cognitive fog) that many PV patients experience with aggressive phlebotomy.[1,2]

Current PV management for high-risk patients centers on cytoreductive therapy — hydroxyurea as first line, ruxolitinib (a JAK1/2 inhibitor) for hydroxyurea-intolerant or -resistant disease.[3] These agents reduce marrow output broadly. Rusfertide offers a mechanistically distinct approach that works specifically on iron-limited erythropoiesis, potentially allowing better hematocrit control as an add-on to existing cytoreductive therapy rather than as a replacement. The VERIFY trial permitted concurrent cytoreductive therapy, so the rusfertide effect was observed on top of background cytoreduction.

Why It Matters Clinically

The practical appeal for patients is real. Repeated therapeutic phlebotomy — every few weeks for some patients — is inconvenient, creates cumulative iron deficiency with its own symptom burden, and requires visits to infusion centers or hematology offices. A once-weekly subcutaneous injection that eliminates or dramatically reduces phlebotomy need addresses a tangible quality-of-life burden in a chronic disease. Patient-reported outcomes in VERIFY showed improvement in fatigue and symptom burden with rusfertide, consistent with the reduction in phlebotomy burden.

Limitations

VERIFY enrolled patients already on background cytoreductive therapy; rusfertide's efficacy as monotherapy without cytoreduction has not been demonstrated in a pivotal trial. Long-term cardiovascular outcomes — stroke and thrombosis — were not powered as primary endpoints; the trial's primary endpoint was a surrogate (hematocrit control). Iron deficiency can cause non-erythropoietic adverse effects; the dose-response relationship between rusfertide-induced functional iron restriction and systemic iron depletion symptoms requires ongoing monitoring. Subcutaneous injection route requires patient training and is not suitable for all patients.